Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00— vs Q2 2021 Net Income-$24.59M-$24.59MN/M vs Q2 2021 EPS, diluted—
Operating Income-$24,007,000N/M Operating Cash Flowderived-$24,422,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$24,422,000N/M ended Jun 30, 2022 · filed Aug 3, 2022 · 34 d after period end